Skip to main content
. Author manuscript; available in PMC: 2019 Sep 16.
Published in final edited form as: Sci Transl Med. 2019 Jul 31;11(503):eaaw4993. doi: 10.1126/scitranslmed.aaw4993

Figure 5. AR-low prostate cancer is more sensitive to disruption of the eIF4E-eIF4G interaction than AR-intact prostate cancer.

Figure 5.

(A) Intact and castrate PtenL/L;4ebp1M primary prostate cancer cells treated with doxycycline for 48 hours. Proliferation was measured using the IncuCyte platform (In = intact, Cx = castrate, assay completed in triplicate, *P = 0.0026, **P = 0.03, t-test).

(B) 4EBP1 protein immunofluorescence quantification of a tissue microarray composed of end-stage metastatic CRPC patient specimens classified by AR protein expression (2–4 tumors sampled per patient, AR low - n = 10, AR high - n = 17, *P = 0.0089, t-test).

(C) Simplified schematic of the mechanism of action of 4E1RCat, 4E2RCat, and 4EGI-1, which disrupt the eIF4E-eIF4G interaction.

(D) Intact and castrate PtenL/L cells treated with 4E2RCat for 48 hours. Proliferation was measured using the IncuCyte platform (In = intact, Cx = castrate, assay completed in triplicate, *P < 0.0001, t-test).

(E) Intact and castrate PtenL/L cells treated with 4EGI-1 for 48 hours. Proliferation was measured using the IncuCyte platform (In = intact, Cx = castrate, assay completed in triplicate, *P = 0.002, t-test).

(F) AR+ parental and AR- APIPC prostate cancer cells treated with 4E2RCat for 48 hours. Proliferation was measured using the IncuCyte platform (assay completed in triplicate, *P < 0.0001, **P = 0.0003, t-test).

(G) AR+ parental and AR- APIPC prostate cancer cells treated with 4EGI-1 for 48 hours. Proliferation was measured using the IncuCyte platform (assay completed in triplicate, *P = 0.0003, t-test).

Data presented as mean +/− SEM.